“…These diseases include systemic autoimmune diseases such as systemic lupus erythematosus 74-76, systemic sclerosis 77, polymyositis 78, vasculitis syndrome including giant cell arteritis 79-84, Takayasu arteritis 79, 82, 85-87, cryoglobulinemia 88, myeloperoxidase-antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis 89 and rheumatoid vasculitis 90. The application of tocilizumab may also extend to organ-specific autoimmune diseases including Crohn's disease 91, relapsing polychondritis 92, 93, acquired hemophilia A 94, autoimmune hemolytic anemia 95, 96, as well as to chronic inflammatory diseases such as adult-onset Still's disease 97-113, amyloid A amyloidosis 114-120, polymyalgia rheumatica 79, 84, 121, remitting seronegative symmetrical synovitis with pitting edema 122, Behcet's disease 123, 124, uveitis 125, graft-versus-host diseases 126, 127, and tumor necrosis factor receptor-associated periodic syndrome 128 ( Table 1 ). Some studies have reported that tocilizumab is efficacious for spondyloarthritis 129-135, although others observed only minor effects 136-138.…”